← Back to Screener
Nuvation Bio Inc. (NUVB)
Price$5.12
Favorite Metrics
Price vs S&P 500 (26W)27.08%
Price vs S&P 500 (4W)10.89%
Market Capitalization$1.77B
All Metrics
Book Value / Share (Quarterly)$0.88
P/TBV (Annual)10.46x
Cash Flow / Share (Quarterly)$-0.52
Price vs S&P 500 (YTD)-47.44%
Gross Margin (TTM)85.22%
Net Profit Margin (TTM)-325.31%
EPS (TTM)$-0.60
10-Day Avg Trading Volume2.83M
EPS Excl Extra (TTM)$-0.60
EPS (Annual)$-0.60
ROI (Annual)-39.81%
Gross Margin (Annual)85.22%
Cash / Share (Quarterly)$1.53
Revenue Growth QoQ (YoY)633.06%
ROA (Last FY)-34.40%
EBITD / Share (TTM)$-0.62
ROE (5Y Avg)-45.89%
Operating Margin (TTM)-338.72%
Cash Flow / Share (Annual)$-0.52
P/B Ratio5.78x
P/B Ratio (Quarterly)10.08x
Net Income / Employee (Annual)$-1
EV / Revenue (TTM)28.78x
Net Interest Coverage (TTM)-24.42x
ROA (TTM)-35.04%
EPS Incl Extra (Annual)$-0.60
Current Ratio (Annual)6.95x
Quick Ratio (Quarterly)6.67x
3-Month Avg Trading Volume5.14M
52-Week Price Return170.21%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$0.85
P/S Ratio (Annual)28.07x
Asset Turnover (Annual)0.11x
52-Week High$9.75
EPS Excl Extra (Annual)$-0.60
CapEx CAGR (5Y)123.44%
26-Week Price Return35.83%
Quick Ratio (Annual)6.67x
13-Week Price Return-19.49%
Total Debt / Equity (Annual)0.68x
Current Ratio (Quarterly)6.95x
Enterprise Value$1,810.044
Asset Turnover (TTM)0.11x
Book Value / Share Growth (5Y)-2.24%
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-325.31%
Cash / Share (Annual)$1.53
3-Month Return Std Dev70.75%
Net Income / Employee (TTM)$-1
ROE (Last FY)-66.93%
EPS Basic Excl Extra (Annual)$-0.60
Receivables Turnover (TTM)4.37x
Total Debt / Equity (Quarterly)0.68x
EPS Incl Extra (TTM)$-0.60
ROI (TTM)-40.13%
P/S Ratio (TTM)28.07x
Revenue / Share (Annual)$0.18
Tangible BV / Share (Annual)$0.85
Price vs S&P 500 (52W)135.12%
Year-to-Date Return-43.30%
5-Day Price Return8.09%
EPS Normalized (Annual)$-0.60
ROA (5Y Avg)-35.67%
Net Profit Margin (Annual)-325.31%
Month-to-Date Return18.41%
Cash Flow / Share (TTM)$-0.38
EBITD / Share (Annual)$-0.62
Operating Margin (Annual)-338.72%
LT Debt / Equity (Annual)0.63x
ROI (5Y Avg)-40.14%
LT Debt / Equity (Quarterly)0.63x
EPS Basic Excl Extra (TTM)$-0.60
P/TBV (Quarterly)10.46x
P/B Ratio (Annual)10.08x
Pretax Margin (TTM)-325.31%
Book Value / Share (Annual)$0.88
Price vs S&P 500 (13W)-22.36%
Beta1.66x
Revenue / Share (TTM)$0.18
ROE (TTM)-57.48%
52-Week Low$1.57
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.19
4.12
4.12
4.12
Industry Peers — Pharmaceuticals(308)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
NUVBNuvation Bio Inc. | 28.07x | — | 85.22% | — | $5.12 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $919.90 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $230.69 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $203.71 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $117.10 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $200.69 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $150.99 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $40.46 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $96.00 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.52 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $59.13 |
About
Nuvation Bio is a biopharmaceutical company developing oncology treatments, with its lead candidate taletrectinib, an oral ROS1 inhibitor for patients with ROS1-positive non-small cell lung cancer. The clinical-stage pipeline includes additional oncology candidates at various development stages. Revenue is generated primarily through licensing agreements and research partnerships, with the majority coming from Japan.